secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001193125-25-115965
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q1 revenue down 7.6% to $41.5M; net loss widens; FY2025 guidance reduced
------------------------------------------------------------------------------

- Revenue $41.5M (-7.6% YoY); gross margin 49% vs 51%; net loss $11.4M vs $6.2M loss prior year.
- Adjusted EBITDA loss $3.3M vs $0.7M loss; cash & securities $265.6M, down $12.3M from Dec 2024.
- FY2025 revenue guidance revised to $196-210M (-2% to +5% YoY); prior guidance withdrawn.
- Repurchased $10.6M of common stock in Q1; launched Cytek Muse Micro instrument.
- Strength in APAC and cell sorters/service business offset by US/EMEA product sales slowdown.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525115965/0001193125-25-115965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525115965/d926849d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-115965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer